Apixaban Teva

/ Teva

Prevention of venous thromboembolism in adult patients following elective hip or knee replacement surgery:
The recommended dose of Apixaban 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. Duration of treatment is recommended for 32-38 days following hip surgery, or 10-14 days following knee surgery.
Prevention of stroke and embolism in adult patients with (non-valvular) atrial fibrillation, with at least one risk factor:
The recommended dose of Apixaban is 5 mg taken orally twice daily.
Dose reduction: The recommended dose of Apixaban is 2.5 mg taken orally
* Severely reduced kidney function.
* At least two of the following criteria are met:
– Creatinine serum value ≥ 1.5 mg/dL
– 80 years or older.
– Body weight is 60 kg or less.
Blood clots in the leg veins and in the lung blood vessels:
The recommended dose of Apixaban is two tablets of 5 mg taken orally twice daily, for first 7 days. After 7 days the recommended dose is one tablet of Apixaban 5 mg twice daily.
Prevention of recurrent blood clots following 6 months of treatment:
The recommended dose of Apixaban 2.5 mg taken orally twice daily.
Please refer to the license holder for further details.

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults.

* Sensitive (allergic) to the active ingredient or to any of the other ingredients this medicine contains.
* Significant active bleeding
* Liver disease leading to a clotting disorder and a risk of bleeding
* Medical condition that increases the risk of bleeding
* Patients that recently had brain, spinal or eye surgery.
* Other anticoagulant treatment
Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.